Edgewise Therapeutics, Inc.EWTXNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+38.2%
5Y CAGR+61.9%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+38.2%/yr
Annual compound
5Y CAGR
+61.9%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
11.1x
Strong expansion
Streak
6 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $189.14M | +19.1% |
| 2024 | $158.83M | +38.9% |
| 2023 | $114.36M | +59.6% |
| 2022 | $71.66M | +65.8% |
| 2021 | $43.22M | +154.1% |
| 2020 | $17.01M | +71.4% |
| 2019 | $9.92M | - |